SOT Annual Meeting and ToxExpo 2026

Presenter: Clare Gilmer, Senior Research Scientist, Certara

Location: Room 23B

In silico tools that rely on input of molecular structure only can flag-up potential safety issues prior to even molecule synthesis and therefore support early de-risking of the drug discovery pipeline. In alignment with the FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies, we are developing new approach methodologies (NAMs) which will help predict some of the most common and impactful preclinical safety issues: hepatotoxicity, QT prolongation and off-target safety.

Presenters: Kevin Snyder, Director of Product, Certara and Melissa Cunningham, Executive Director, Product Management, Certara

Location: Room 23B

This session will showcase two complementary innovations for toxicology data analysis. First, learn how Certara’s SEND Data Lake enables structured storage and integration of CDISC-SEND-formatted study data to support advanced analytics, predictive modeling, and large-scale cross-study analysis using open-source tools. Second, explore AI-enabled functionality designed to help users rapidly identify endpoints of interest and automatically generate narrative summaries that describe the toxicological relevance of study findings. Together, these approaches accelerate interpretation and decision-making within a collaborative data science framework.

Presenter: Barira Islam, Associate Principal Scientist, Certara

Location: Ballroom 6F

This presentation is part of the session, “NAM in vitro Assessment of Intestinal Metabolism to Inform PBPK Modeling of Bioavailability and Systemic Exposure”

Authors: S. Davidse1, L. Xu1, E. Lymperi1, T. Danilyuk1, B. Islam2, S. Kunnen1, P. Bouwman1, L. Wijaya1, and B. van de Water1. 1Leiden University (LACDR), Leiden, Netherlands; and 2Certara, Sheffield, United Kingdom

Poster information: Poster Board Number F500

Authors: A. De Carvalho E Silva1, A. D. Kalian2, D. McDonald3, S. He3, G. D. Loizou1, K. McNally4, A. M. C. Iserte5, O. J. Osborne6, C. Potter6, J. K. Colbourne1, and M. R. Viant1. 1Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom; 2King’s College London, London, United Kingdom; 3AIA Insights, Birmingham, United Kingdom; 4Predictive Technologies Division, Certara UK Ltd, Sheffield, United Kingdom; 5Health & Biomedicine Department, LEITAT, Barcelona, Spain; and 6UK Food Standards Agency, London, United Kingdom

Poster information: Poster Board Number M836

Authors: Y. Chen1, T. Arndt1, E. Debien1, K. Snyder2, S. Nakatsuji1, J. Forget1, and W. Davis1. 1Altasciences, Seattle, WA; and 2Certara, Radnor, PA.

Poster information: Abstract #4054 | Poster Board Number G528 | Poster Session: Safety Assessment: Pharmaceutical-Drug Development I

Authors: N. Tahir1, I. Bruns1, L. van Schijndel2, J. Rousel2, D. R. Pereira2, M. Moerland2, S. Fu3, N. Quignot3, F. Y. Bois3, M. J. Moné1, G. Callegaro1, S. Le Dévédec1, M. Niemeijer1, and B. van de Water1. 1Division of Cell Systems and Drug Safety, LACDR, Leiden University, Leiden, Netherlands; 2Centre for Human Drug Research, Leiden, Netherlands; and 3CERTARA, Paris, France

Poster information: Poster Board Number F445

Authors: N. Tahir1, I. B. Bruns1, L. v. Schijndel2, J. Rousel2, M. v. Diemen2, D. R. Pereira2, M. Moerland2, S. Fu3, N. Quignot3, F. Y. Bois3, M. J. Moné1, G. Callegaro1, S. L. Dévédec1, M. Niemeijer1, and B. v. Water1. 1Leiden Academic Centre for Drug Research, Leiden, Netherlands; 2Centre for Human Drug Research, Leiden, Netherlands; and 3Certara, Paris, France

Poster information: Poster Board Number F446

Authors:  K. J. Sadko1, A. VandenBussche1, M. Bailie2, and A. Lauver1. 1Michigan State University, East Lansing, MI; and 2Certara Inc., Radnor, PA.

Poster information: Abstract #4713 | Poster Board Number F504 | Poster Session: Safety Assessment: Pharmaceutical-Drug Development II